MAIA advances novel telomere-targeting agent under FDA s Fast Track designation Further data from Thio-101 Part C may support accelerated approval filing with FDA Chicago, Nov. 17, 2026 Globe Newswire -- Maia Biotechnolo
Why Is MAIA Biotechnology, Inc. (MAIA) Stock Down Today?
Updated Nov 22, 2026 5:31 AM ET ยท Prev Close $1.14
Session Regime & Catalyst Assessment
68% Signal ConvictionMAIA Biotechnology, Inc. Pulling Back 2.63% on 1.03x Relative Volume
MAIA Biotechnology, Inc. (MAIA) is pulling back 2.63% (-$0.03) to $1.11 on 1.03x average session volume. Relative to benchmarks, MAIA is outperforming the S&P 500 by +1.01%. 14-day RSI stands at 48.8, keeping momentum in a bearish regime.
MAIA advances novel telomere-targeting agent under FDA s Fast Track designation Further data from Thio-101 Part C may support accelerated approval filing with FDA Chicago, Nov. 17, 2026 Globe Newswire -- Maia Biotechnolo
Price ($1.11) trades relative to 20-day SMA ($1.11) and 50-day SMA ($1.17).
Market & Sector Relative Strength
MAIA outperforming the S&P 500 by +1.01%Recent MAIA Catalyst Headlines
Verified WireNew York, Nov. 12, 2026 Globe Newswire -- Diamond Equity Research, an equity research firm with a focus on small capitalization public companies has released an update note on MAIA Biotechnology, Inc. NYSE Maia . The res
Enrollment completed in Part C of Thio-101 Phase 2 study 65 of 2026 enrollment target reached in pivotal Thio-104 Phase 3 study Chicago, Oct. 07, 2026 Globe Newswire -- Maia Biotechnology, Inc. NYSE American Maia Maia ,
Thio-104 advances toward key 2027 interim survival analysis Chicago, Sept. 23, 2026 Globe Newswire -- Maia Biotechnology, Inc. NYSE American Maia Maia , the Company , a clinical-stage biopharmaceutical company focused on
1โ3 Day Expected Range & Key Level
54% Follow-ThroughMonitor volume expansion above 1.5x RVOL around $1.11 (20-day SMA support) for directional breakout confirmation.
Technical Regime (MAIA)
MIXED MA TRENDRetail & Crowd Sentiment
Very BullishA bullish StockTwits message suggests that big pharma companies may be interested in acquiring $MAIA due to the potential for expanding the market for its 3-letter treatment into a 1-letter market, leading to significant acquisition value.
About MAIA Biotechnology, Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. Thio (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor โฆ
Get Instant MAIA Catalyst Alerts
Receive an email alert when MAIA triggers an unusual volume breakout, options sweep, or rating shift.
MAIA Session & Catalyst FAQ
Why is MAIA stock down today?
MAIA Biotechnology, Inc. (MAIA) is pulling back 2.63% (-$0.03) to $1.11 on 1.03x average session volume. Relative to benchmarks, MAIA is outperforming the S&P 500 by +1.01%. 14-day RSI stands at 48.8, keeping momentum in a bearish regime.
Is MAIA stock a buy or sell right now?
Today's session carries a 68% catalyst conviction score on 1.03x relative volume (moderate participation). Our multi-factor model currently rates MAIA as AVOID NEW MONEY. Review full valuation, quality, and timing signals on the MAIA Buy or Sell Decision Brief โ
What is MAIA's intrinsic value and expected trading range?
At $1.11, MAIA's modeled 1-to-3 session range is $1.05 โ $1.17, with a key inflection level at $1.11 (20-day SMA support). Compare current price against multi-year cash flow projections in the MAIA Intrinsic Value & DCF Model โ and Market Cycle Phase Tracker โ
What do RSI and moving averages signal for MAIA?
RSI at 48.8 reflects soft below-midline momentum. MAIA trades at $1.11 relative to its 20-day SMA ($1.11) and 50-day SMA ($1.17), reflecting a mixed moving-average structure.
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.